Structure-based design of nucleoside-derived analogues as sulfotransferase inhibitors. 2019

Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
Department of Chemistry, University of Liverpool Liverpool L69 7ZD UK nkershaw@liverpool.ac.uk.

Sulfotransferases (STs) catalyse the transfer of a sulfonyl group ('sulfation') from the enzyme co-factor 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to a variety of biomolecules. Tyrosine sulfation of proteins and carbohydrate sulfation play a crucial role in many protein-protein interactions and cell signalling pathways in the extracellular matrix. This is catalysed by several membrane-bound STs, including tyrosylprotein sulfotransferase 1 (TPST1) and heparan sulfate 2-O-sulfotransferase (HS2ST1). Recently, involvement of these enzymes and their post-translational modifications in a growing number of disease areas has been reported, including inflammation, cancer and Alzheimer's disease. Despite their growing importance, the development of small molecules to probe the biological effect of TPST and carbohydrate ST inhibition remains in its infancy. We have used a structure-based approach and molecular docking to design a library of adenosine 3',5'-diphosphate (PAP) and PAPS mimetics based upon 2'-deoxyadenosine and using 2'-deoxy-PAP as a benchmark. The use of allyl groups as masked methyl esters was exploited in the synthesis of PAP-mimetics, and click chemistry was employed for the divergent synthesis of a series of PAPS-mimetics. A suite of in vitro assays employing TPST1 and HS2ST, and a kinase counter screen, were used to evaluate inhibitory parameters and relative specificity for the STs.

UI MeSH Term Description Entries

Related Publications

Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
June 1994, Drug design and discovery,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
July 1995, Acta crystallographica. Section D, Biological crystallography,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
February 1993, Farmaco (Societa chimica italiana : 1989),
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
March 2003, Bioorganic & medicinal chemistry letters,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
June 2015, Journal of medicinal chemistry,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
January 1998, Advances in experimental medicine and biology,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
July 1994, Journal of medicinal chemistry,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
June 2018, European journal of medicinal chemistry,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
January 2016, Nucleosides, nucleotides & nucleic acids,
Neil M Kershaw, and Dominic P Byrne, and Hollie Parsons, and Neil G Berry, and David G Fernig, and Patrick A Eyers, and Richard Cosstick
February 2014, Antiviral research,
Copied contents to your clipboard!